BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 26159916)

  • 21. Transcriptome sequencing in pediatric acute lymphoblastic leukemia identifies fusion genes associated with distinct DNA methylation profiles.
    Marincevic-Zuniga Y; Dahlberg J; Nilsson S; Raine A; Nystedt S; Lindqvist CM; Berglund EC; Abrahamsson J; Cavelier L; Forestier E; Heyman M; Lönnerholm G; Nordlund J; Syvänen AC
    J Hematol Oncol; 2017 Aug; 10(1):148. PubMed ID: 28806978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lrig1 is a positive prognostic marker in hepatocellular carcinoma.
    Yang B; Dai C; Tan R; Zhang B; Meng X; Ye J; Wang X; Wei L; He F; Chen Z
    Onco Targets Ther; 2016; 9():7071-7079. PubMed ID: 27895499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.
    Cheng SQ; Fan HY; Xu X; Gao WW; Lv SG; Ye MH; Wu MJ; Shen XL; Cheng ZJ; Zhu XG; Zhang Y
    J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):558-563. PubMed ID: 27465333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SH3GL1 inhibition reverses multidrug resistance in colorectal cancer cells by downregulation of MDR1/P-glycoprotein via EGFR/ERK/AP-1 pathway.
    Guan H; Zhao P; Dai Z; Liu X; Wang X
    Tumour Biol; 2016 Sep; 37(9):12153-12160. PubMed ID: 27220321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer.
    Yan W; Wu K; Herman JG; Xu X; Yang Y; Dai G; Guo M
    Clin Epigenetics; 2018; 10():69. PubMed ID: 29796120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic silencing of NDRG2 promotes colorectal cancer proliferation and invasion.
    Hong SN; Kim SJ; Kim ER; Chang DK; Kim YH
    J Gastroenterol Hepatol; 2016 Jan; 31(1):164-71. PubMed ID: 26250123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LRIG1 expression in colorectal cancer.
    Ljuslinder I; Golovleva I; Palmqvist R; Oberg A; Stenling R; Jonsson Y; Hedman H; Henriksson R; Malmer B
    Acta Oncol; 2007; 46(8):1118-22. PubMed ID: 17851870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
    Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
    Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth.
    Li H; Li J; Su Y; Fan Y; Guo X; Li L; Su X; Rong R; Ying J; Mo X; Liu K; Zhang Z; Yang F; Jiang G; Wang J; Zhang Y; Ma D; Tao Q; Han W
    Oncogene; 2014 Jun; 33(24):3109-18. PubMed ID: 23893243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer.
    Kou C; Zhou T; Han X; Zhuang H; Qian H
    Biochem Biophys Res Commun; 2015 Aug; 464(2):519-25. PubMed ID: 26159916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor.
    Ji Y; Kumar R; Gokhale A; Chao HP; Rycaj K; Chen X; Li Q; Tang DG
    Semin Cancer Biol; 2022 Jul; 82():120-133. PubMed ID: 33476721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The LRIG family: enigmatic regulators of growth factor receptor signaling.
    Simion C; Cedano-Prieto ME; Sweeney C
    Endocr Relat Cancer; 2014; 21(6):R431-43. PubMed ID: 25183430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers.
    Malik U; Javed A
    Curr Cancer Drug Targets; 2017; 17(1):3-16. PubMed ID: 27628597
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.